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Summary
Background: Children undergoing strabismus surgery have a high
incidence of postoperative vomiting (POV). The purpose of this study
was to assess the efficacy and safety of dolasetron for the prevention of
emesis comparing a single 0.35 mgÆkg)1 or 12.5 mg dose with placebo.
Methods: Children aged 2–12 years with an ASA status of 1 or 2
undergoing strabismus surgery were randomized in a double-blind
manner to one of three treatment groups. Patients were excluded with
a history of previous postoperative vomiting or motion sickness,
allergy to serotonin receptor antagonists or previous antiemetic
administration within 24 h prior to enrollment.
General anaesthesia was induced with sevoflurane and N2O/O2
and maintained with isoflurane and N2O/O2. The study medication
was administered 15 min prior to the end of surgery. Patients
experiencing two or more episodes of vomiting were rescued in the
postanaesthesia care unit (PACU) with metoclopramide 0.15 mgÆkg)1.
A total of 118 patients were enrolled with documentation of the
number and severity of vomiting episodes, time to awakening, PACU
length of stay and postoperative agitation.
Results: Patients with an acute complete response (ACR), defined as no
emetic episodes and no rescue medication within 24 h of study drug
administration were 62% (weight dose), 64% (fixed dose) and 33%
(placebo, P < 0.05).
Conclusions: There was no statistical difference between the
0.35 mgÆkg)1 dose and the fixed 12.5 mg dose of dolasetron with both
reducing the incidence of POV.
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Introduction
The incidence of postoperative vomiting (POV) in
children varies from 5 to 80% (1) and is dependent
upon patient-related factors, surgical procedure,
anaesthetic agents and postoperative management
(2). POV is a leading cause of morbidity in paediatric
surgical patients and may be associated with wound
dehiscence, pulmonary aspiration, bleeding, dehy-
dration and electrolyte disturbance (3). Furthermore,
POV may result in unanticipated hospital admis-
sion, prolonged length of stay, increased health care
costs and decreased patient satisfaction.
Postoperative vomiting is mediated by a variety of
receptors including dopaminergic, muscarinic, sero-
tonergic, histamine and opioid receptors but no single
pharmacological agent is currently available to ant-
agonize all of the receptors involved in the emetic
reflex response. The serotonin receptor antagonists [5-
hydroxytryptamine (5-HT3)] were first introduced to
prevent chemotherapy induced nausea and vomiting
and were found to be highly effective and well-
tolerated (4). Their antiemetic effects may be the result
of the activity at both peripheral neural and central
nervous system sites by blocking the effects of
serotonin in the chemoreceptor trigger zone (CTZ),
nucleus tractus solitarius, and vagal afferents (5).
Prophylactic administration of ondansetron and
granisetron 5-HT3 receptor antagonists have been
shown to reduce the incidence of postoperative
nausea and vomiting (PONV) in children undergoing
strabismus surgery (6,7). A recent study by Sukhani
demonstrated comparative efficacy between ondanse-
tron and dolasetron in combination with dexameth-
asone for POV prophylaxis in children undergoing
ambulatory tonsillectomy (8). Pharmacokinetics have
been studied in paediatrics (9), however dose finding
data in this population are still needed. The purpose
of this randomized, double-blind, placebo-controlled
trial was to compare the safety and efficacy of
intravenous (i.v.) dolasetron in doses of 0.35 mgÆkg)1
(maximum dose 12.5 mg) or a single fixed dose of
12.5 mg, compared with placebo for the prevention of
POV following strabismus repair in children.
Methodology
Following approval from the Institutional Review
Board and written informed consent from a parent
or legal guardian, children aged 2–12 years of age,
with an ASA classification of 1–2, scheduled for
outpatient strabismus surgery were enrolled. Chil-
dren with the following conditions were excluded:
allergy to 5-HT3 agents, previous POV, motion
sickness, hepatic, renal, cardiac or neurological
disorders, and use of an antiemetic within 24 h of
surgery. Children were randomly assigned to one of
the three study groups using a 2 : 2 : 1 randomiza-
tion schedule. The dose per weight group received
0.35 mgÆkg)1 dolasetron, the standard dose group a
fixed dose of 12.5 mg of dolasetron, and the third
group received placebo of sodium chloride 0.9%. All
study drug was provided in an identical volume for
all three arms of the study. The pharmacist at the site
was responsible for the blinding and preparation of
the drug.
Preoperatively, all children received acetamino-
phen (15 mgÆkg)1) orally 30 min prior to induction,
and midazolam was administered at the discretion
of the attending anaesthesiologist. General anaes-
thesia was induced with sevoflurane and nitrous
oxide (60%) in oxygen via facemask. A laryngeal
mask airway (LMATM) was placed and anaesthesia
was maintained with isoflurane in nitrous oxide/
oxygen. An i.v. line was started, and i.v. fluids were
administered as per preexisting guidelines to replace
preoperative deficits and provide standard mainten-
ance fluids. Prior to surgical incision, ketorolac
0.5 mgÆkg)1 i.v. was administered. Atropine
20 lgÆkg)1 i.v. was administered as needed to treat
oculocardiac reflex. Fifteen minutes prior to the end
of the procedure, the study drug was administered.
At the completion of surgery, the patient was turned
to one side, the LMA was removed with the cuff
inflated and the oropharynx suctioned.
Postoperatively, children were monitored for any
episode of POV or retching. The severity of POV
was classified as mild (one episode), moderate (two
episodes), or severe (three or more episodes). Two or
more episodes of vomiting or retching were treated
with metoclopramide 0.15 mgÆkg)1 i.v. (maximum
10 mg). The primary efficacy measure was an acute
complete response (ACR) which was defined as no
POV or rescue antiemetic medication use within
24 h. Postoperative pain was assessed using the
Faces, Legs, Activity Cry and Consolability (FLACC)
observational pain scale (10), and children with
scores of ‡4 were treated with morphine sulphate
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0.05–0.1 mgÆkg)1 i.v. at the discretion of the postan-
aesthesia care unit (PACU) nurse.
The time to awakening and the length of stay
in the PACU were recorded. Adverse events inclu-
ding postoperative agitation were documented.
The parents were telephoned the following day to
obtain the following information: the occurrence
and severity of POV on the trip home and within
24 h, medications administered, adverse events,
and parental satisfaction with the prevention and
treatment of POV using a 1–4 scale (1 ¼ very
dissatisfied, 2 ¼ dissatisfied, 3 ¼ satisfied, 4 ¼ very
very satisfied).
Statistical methods
Categorical data such as ACR, and the incidence and
severity of POV were compared using chi-square
with Fisher’s exact tests as appropriate. Parametric
data such as patient age, and weight were compared
using unpaired t-tests. Data are reported as
mean ± SD or n(%) as appropriate. P values of
£0.05 were considered statistically significant. A
power analysis performed prior to this investigation
demonstrated that 20 patients per group would be
sufficient to detect a reduction of 60% in the
incidence of POV in 24 h assuming an incidence of
70% in the placebo group (a ¼ 0.05; b ¼ 0.20). In
order to reduce exposure to placebo, while provi-
ding sufficient number of subjects to allow evalua-
tion of the safety and efficacy of each dosing group, a
2 : 2 : 1 assignment to treatment and control groups,
respectively, was used.
Results
A total of 118 children were enrolled and included in
the intent-to-treat population (46, 48 and 24 in the
dose per weight group, fixed dose and placebo
groups, respectively). Nineteen children required
tracheal intubation instead of an LMA, and three
received halothane in place of sevoflurane. POV data
were missing for two children as they were lost to
follow-up. Data from each of these children were
therefore excluded from analysis, which resulted in
a total of 94 children enrolled. Demographic and
perioperative data were similar between the three
study groups (Table 1).
Data regarding POV, rescue medications and
other outcome measures are presented in Table 2.
The ACR was significantly lower for children who
received placebo compared with those who received
dolasetron in either the fixed dose or dose per
weight. There was no difference in ACR between
the two active treatment groups. Furthermore,
the ACR was significantly lower in patients who
received morphine (46%) compared with those who
did not (66%; P ¼ 0.05). The median times to first
emetic episode were 195 ± 63 min, 255 ± 105 min
and 188 ± 41 min for 0.35 mgÆkg)1, 12.5 mg dolase-
tron and placebo groups, respectively. Children
who vomited in the hospital had a significantly
longer PACU stay compared with those who did
not vomit (141 ± 59 vs 105 ± 26 min respectively;
P < 0.001). In all groups 94–97% of parents were
satisfied to very satisfied with the care and no
children were admitted to the hospital as a result of
Table 1
Demographic and perioperative







Age 4.8 ± 3 5.3 ± 3 5.4 ± 3
Weight (kg) 20.4 ± 8.9 22.6 ± 10.3 22.1 ± 9.5
Male gender 18 (49%) 19 (48%) 7 (39%)
ASA status
ASA 1 28 (78%) 33 (83%) 14 (78%)
ASA 2 7 (19%) 7 (18%) 4 (22%)
Midazolam (n/%) (mgÆkg)1) 3/8 (0.5 ± 0.08) 2/5 (0.3 ± 0.15) 2/11 (0.5 ± 0.03)
Morphine (n/%) (mgÆkg)1) 17/44 (0.06 ± 0.03) 15/38 (0.06 ± 0.2) 7/39 (0.05 ± 0.02)
Atropine (n/%) 2/6 3/8 0
Anaesthesia duration (min) 63 ± 19 60 ± 16 61 ± 13
Dolasetron dose (mgÆkg)1) 0.35 ± 0.01 0.67 ± 0.28* NA
*P < 0.001 compared with dose per weight group.
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POV. More parents of children with moderate to
severe vomiting were dissatisfied with their child’s
care (12%) compared with those whose children
had none or mild vomiting across all groups (0%;
P ¼ 0.02).
Discussion
This study demonstrates that prophylactic adminis-
tration of i.v. dolasetron in a fixed dose of 12.5 mg or
in a per weight dose of 0.35 mgÆkg)1 reduces the
incidence and severity of POV in children undergo-
ing strabismus surgery compared with placebo
while in the hospital. There were no differences in
the incidence or severity of POV nor in adverse
events between the two dolasetron doses. However,
this study may have been underpowered to detect
such differences.
Dolasetron has been shown to be safe and effect-
ive in treating PONV in adults at doses of 12.5 mg
(11). Previous pharmacokinetic data have demon-
strated that the clearance of dolasetron is greater in
children compared with adults, possibly because of
increased drug metabolism (9). Therefore, higher
doses of dolasetron may be required to prevent or
reduce nausea and vomiting in children. A recent
study demonstrated that 0.6–2.4 mgÆkg)1 of dolase-
tron reduced chemotherapy-induced nausea and
vomiting in children aged 2–17 years, however,
there were insufficient data to determine statistical
differences (12). Yet, the current dolasetron package
insert recommends a dose of 0.35 mgÆkg)1 (maxi-
mum 12.5 mg) for patients aged 2–16 years. Our
data suggest that dolasetron administered i.v. in a
fixed dose of 12.5 mg or as a per weight dose of
0.35 mgÆkg)1 effectively reduces POV in children
undergoing strabismus surgery. Additionally the
long half-life of the active metabolite hydrodolase-
tron may provide prolonged benefit for delayed
emesis (9,13).
This study demonstrated no advantage nor dis-
advantage between the fixed or per weight doses in
terms of efficacy or side-effects. Headache was the
most frequently reported adverse event across all
groups, and was not significantly different for either
dosing group compared with placebo, and was
similar to its reported incidence in previous studies
(12). Seventeen children in the 12.5 mg fixed dose
group received doses of ‡0.7 mgÆkg)1, twice the
weight based dose, to a maximum of 1.25 mgÆkg)1
(one patient) with no difference in the occurrence
of adverse events. Our sample of these children,
however, may have been too small to detect
such differences. Administration of a fixed dose of
dolasetron has the advantages of efficient adminis-







POV in hospital 6 (17%) 8 (21%) 9 (50%)*
POV at home 14 (38%) 13 (33%) 9 (50%)
Rescue antiemetic administered 2 (6%) 3 (8%) 5 (28%)**
Vomiting severity
Mild (one episode) 4 (11%) 5 (13%) 3 (17%)
Moderate (two episodes) 3 (8%) 2 (5%) 2 (11%)
Severe (‡3 episodes) 7 (19%) 7 (18%) 7 (39%)
ACR 23 (62%) 25 (64%) 6 (33%)*
Relative risk (CI)a 0.57 (0.34–0.96) 0.53 (0.32–0.92)
Adverse effects
Headache 6 (18%) 10 (27%) 6 (33%)
Abdominal pain 4 (12%) 2 (5%) 3 (17%)
Constipation 3 (8%) 0 0
PACU length of stay (min) 113 ± 42 108 ± 39 124 ± 31
*P £ 0.044 compared with either treatment group.
**P ¼ 0.032 compared with weight dose.
aRelative risk reduction of postoperative vomiting (POV) in 24 h compared with placebo. CI,
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weight-based dose may offer a small cost advantage
through use of the multidose vial preparation. Other
5-HT3 inhibitors, such as ondansetron, have been
shown to reduce POV in paediatric strabismus
surgery (14). Dolasetron offers a safe and effective
alternative to ondansetron, at approximately half the
acquisition cost. The nature and incidence of side-
effects are similar for each of the 5-HT3 inhibitor
antiemetics with mild ECG changes being reported
(11). These changes however have not been seen in
dolasetron doses of 12.5 mg in paediatric patients for
the prevention of PONV, nor were noted in any of
the study patients enrolled (15).
Several factors likely contributed to POV equally
across our study groups. All children in our
sample received nitrous oxide as a cost-efficient
anaesthetic agent, which has been shown to con-
tribute to POV (16). Furthermore, the use of opioid
analgesics was found to significantly increase the
incidence of POV in our sample. Using alternative
methods of anaesthesia and analgesia may further
reduce POV in children undergoing high-risk
emetogenic surgery. In this study the results were
not effected by the choice of anaesthetic technique
as all patients received a standardized technique.
Furthermore, POV prevention may be enhanced by
combining antiemetics that act on different receptor
sites (11).
Prophylactic administration of antiemetics has
been recommended for patients at high risk for
POV, such as children undergoing strabismus
surgery (11). The choice of antiemetic for preven-
tion of POV should be based on the patient’s risk
factors, the cost of the drug and the potential for
adverse effects. The 5-HT3 antagonists offer a well-
tolerated and effective group of agents for the
prevention and treatment of POV in children.
Dolasetron may represent the most cost-effective
agent in this class of drugs. This study demonstra-
ted that dolasetron administered intravenously in a
fixed dose of 12.5 mg or in a 0.35 mgÆkg)1 (maxi-
mum of 12.5 mg) dose at the end of surgery
reduced the incidence and severity of POV in
children undergoing strabismus surgery. Further
study in a larger sample may be necessary to
determine the risk benefit ratio for the fixed vs per
weight dose.
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